MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209–11.10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. The Lancet, 2014, 383(9927): 1490–502. 10.1016/S0140-6736(13)61649-9.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin, 2022, 72(4): 372–401.10.3322/caac.21728.
   PubMed Web of Science ®Google Scholar
• Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the development of miRNA bioinformatics tools. Brief Bioinform, 2019, 20(5): 1836–52.10.1093/bib/bby054.
   PubMed Web of Science ®Google Scholar
• Achkar NP, Cambiagno DA. Manavella PA. miRNA Biogenesis: a Dynamic Pathway. Trends Plant Sci, 2016, 21(12): 1034–44.10.1016/j.tplants.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nature Structural & Molecular Biology, 2012, 19(6): 586–93.10.1038/nsmb.2296.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRnas: biology, functions, therapeutics, and analysis methods. J Cell Physiol, 2019, 234(5): 5451–65. 10.1002/jcp.27486.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu YY, Chen Y, Zhang L, Wang R, Ding X, Zhang H, Zhang CY, Zhang C, Gu WJ, et al. Urinary-derived extracellular vesicle microRNAs as non-invasive diagnostic biomarkers for early-stage renal cell carcinoma. Clin Chim Acta, 2024, 552: 117672. 10.1016/j.cca.2023.117672.
   PubMed Web of Science ®Google Scholar
• Liu D, Jin Y, Wu J, Zhu H, Ye D. MiR-135b-5p is an oncogene in pancreatic cancer to regulate GPRC5A expression by targeting transcription factor KLF4. Cell Death Discov, 2022, 8(1): 23.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Jiang J, Zhang W, Sun L, Ge Q, Li C, Li X, Li X, Shi S. Identification of cuproptosis-related miRNAs in triple-negative breast cancer and analysis of the miRNA-mRNA regulatory network. Heliyon, 2024, 10(7): e28242. 10.1016/j.heliyon.2024.e28242.
   PubMed Web of Science ®Google Scholar
• Yu S, Yu M, Chen J, Tang H, Gong W, Tan H. Circ_0000471 suppresses the progression of ovarian cancer through mediating mir-135b-5p/dusp5 axis. Am J Reprod Immunol, 2023, 89(4): e13651.10.1111/aji.13651.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li Y, Wu T, Li Y, Wang Q. Astragaloside IV Attenuates programmed death-ligand 1-mediated immunosuppression during liver cancer development via the miR-135b-5p/CNDP1 axis. Cancers (Basel), 2023, 15(20). 5048 10.3390/cancers15205048.
   PubMed Web of Science ®Google Scholar
• Fornasier G, Francescon S, Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Adv Ther, 2018, 35(10): 1497–509.10.1007/s12325-018-0791-0.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Dell’aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R. Aprile G, et al., Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol, 2019, 5(3): 343–50. 10.1001/jamaoncol.2018.5080.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, et al., Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol, 2012, 23(9): 2313–18. 10.1093/annonc/mdr623.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H, et al., lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med, 2017, 23(11): 1331–41. 10.1038/nm.4424.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst, 2017, 109(8).10.1093/jnci/djw332.
   Google Scholar
• Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang YR, Xu J, Wei W, Kang-Sheng G. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Disease, 2019, 10(4): 252.10.1038/s41419-019-1479-3.
   PubMed Web of Science ®Google Scholar
• Zhao C, Mo L, Li C, Han S, Zhao W, Liu L. FOXN3 suppresses the growth and invasion of papillary thyroid cancer through the inactivation of Wnt/β-catenin pathway. Mol Cell Endocrinol, 2020, 515: 110925.10.1016/j.mce.2020.110925.
   PubMed Web of Science ®Google Scholar
• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol, 2021, 14(10): 101174.10.1016/j.tranon.2021.101174.
   PubMed Web of Science ®Google Scholar
• Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C. Vitiello PP, et al., Cetuximab rechallenge plus avelumab in pretreated patients with ras wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE Trial. JAMA Oncol, 2021, 7(10): 1529–35. 10.1001/jamaoncol.2021.2915.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, et al., Encorafenib plus cetuximab as a new standard of care for previously treated braf v600e–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol, 2021, 39(4): 273–84. 10.1200/JCO.20.02088.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351(4): 337–45. 10.1056/NEJMoa033025.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al., Cetuximab for the treatment of colorectal cancer. N Engl J Med, 2007, 357(20): 2040–48. 10.1056/NEJMoa071834.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhu X, Yu Y, Zhu W, Jin L, Zhang X, Li S, Zou P, Xie C, Cui R. Dissecting miRNA signature in colorectal cancer progression and metastasis. Cancer Lett, 2021, 501: 66–82.10.1016/j.canlet.2020.12.025.
   PubMed Web of Science ®Google Scholar
• Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet, 2022, 38(6): 613–26.10.1016/j.tig.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci, 2020, 21(5).10.3390/ijms21051723.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang X, Mi Z, Jiang X, Sun L, Zheng B, Wang J, Meng M, Zhang L. Wang Z, et al., STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer. Cell Death Dis, 2021, 12(5): 493. 10.1038/s41419-021-03773-x.
   PubMed Web of Science ®Google Scholar
• Li J, Sun L, Chen Y, Zhu J, Shen J, Wang J, Gu Y, Zhang G, Wang M. Shi T, et al., Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1. Cancer Immunol Immunother, 2022, 71(2): 311–25. 10.1007/s00262-021-02991-8.
   PubMed Web of Science ®Google Scholar
• Li Z, Qin Y, Chen P, Luo Q, Shi H, Jiang X. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2. Int J Mol Med, 2020, 46(4): 1514–24.10.3892/ijmm.2020.4681.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Xin ZM., Zhang, Q., Chen, X. MiR-135b-5p inhibits the progression of malignant melanoma cells by targeting RBX1. Eur Rev Med Pharmacol Sci, 2420, 20(1): 1309–15. 10.1186/s12935-020-01386-6.
   Google Scholar
• Wang H, Wang X, Zhang H, Deng T, Liu R, Liu Y, Li H, Bai M, Ning T. Wang J, et al. The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer. Oncogene, 2021, 40(28): 4695–708. 10.1038/s41388-021-01898-z.
   PubMed Web of Science ®Google Scholar
• Lv ZD, Xin HN, Yang ZC, Wang WJ, Dong JJ, Jin LY, Li FN. miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer. J Cell Physiol, 2019, 234(7): 10819–26.10.1002/jcp.27906.
   PubMed Web of Science ®Google Scholar
• Xiang S, Fang J, Wang S, Deng B, Zhu L. MicroRNA‑135b regulates the stability of PTEN and promotes glycolysis by targeting USP13 in human colorectal cancers. Oncol Rep, 2015, 33(3): 1342–48. 10.3892/or.2014.3694.
   PubMed Web of Science ®Google Scholar
• Kong X, Zhai J, Yan C, Song Y, Wang J, Bai X, Brown JaL, Fang Y. Recent advances in understanding FOXN3 in breast cancer, and other malignancies. Front Oncol, 2019, 9: 234.10.3389/fonc.2019.00234.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, Zhang Y, Liu S, Yang J, Xu B, et al., The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest, 2017, 127(9): 3421–40. 10.1172/JCI94233.
   PubMed Web of Science ®Google Scholar
• Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F, Tian H, Chen T, Yao M, Li J. The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells. Oncotarget, 2016, 7(28): 43534–45.10.18632/oncotarget.9780.
   PubMedGoogle Scholar
• Yu W, Diao Y, Zhang Y, Shi Y, Lv X, Zhang C, Zhang K, Yao W, Huang D, Zhang J. Bioinformatic analysis of FOXN3 expression and prognostic value in pancreatic cancer. Front Oncol query, 2022, 12: 1008100. 10.3389/fonc.2022.1008100.
   PubMedGoogle Scholar
• Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci, 2020, 21(3). 1102 10.3390/ijms21031102.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol, 2020, 13(1): 165.10.1186/s13045-020-00990-3.
   PubMed Web of Science ®Google Scholar
• Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L, Zhang W, Li S, Xu Q. Zhong M, et al., ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res, 2022, 41(1): 15. 10.1186/s13046-021-02229-6.
   PubMed Web of Science ®Google Scholar
• Patel M, Horgan PG, Mcmillan DC, Edwards J. NF-κB pathways in the development and progression of colorectal cancer. Transl Res, 2018, 197: 43–56.10.1016/j.trsl.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Sun M, Ma X, Tu C, Wang X, Qu J, Wang S, Xiao S. MicroRNA-378 regulates epithelial-mesenchymal transition and metastasis of melanoma by inhibiting FOXN3 expression through the Wnt/β-catenin pathway. Cell Biol Int, 2019, 43(10): 1113–24. 10.1002/cbin.11027.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu Z, Wen C, Liao Q, He B, Peng J, Tang X, Chen Z, Xie Y. MicroRNA-182 promotes epithelial-mesenchymal transition by targeting FOXN3 in gallbladder cancer. Oncol Lett, 2021, 21(3): 200.10.3892/ol.2021.12461.
   PubMed Web of Science ®Google Scholar